LYmph Node eXamination in Cat Allergen Immunotherapy

NCT07447869 | Recruiting Early Phase 1 DMC

• 1 other identifier: DAIT ITN102AD
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

Sixteen eligible cat-allergic participants will be accrued in the study. Eight participants who have been on subcutaneous immunotherapy (SCIT) at maintenance dosing for at least 1 year will be assigned to the SCIT cohort, and 8 participants who have never been on cat immunotherapy will be assigned to the No immunotherapy (IT) cohort. Participants will undergo intradermal cat allergen challenge in bilateral upper arms at baseline (Day 1), will undergo axillary lymph node and peripheral blood sampling at Day 4, and axillary lymph node, peripheral blood, and adenoid and nasal sampling at Week 3. The primary objective is to determine the number of analyzable cells from axillary lymph node fine-needle aspiration 3 days and 3 weeks after intradermal cat allergen challenge in two cohorts of cat-allergic participants: those undergoing cat allergen immunotherapy and those who are not receiving this treatment

Conditions

Allergy

Keywords

cat allergen; subcutaneous immunotherapy; immunotherapy

Outcome Measures

Primary Outcomes (1)

• Total number of analyzable cells from the lymph node fine-needle aspiration

  The total number of analyzable cells per Fine-Needle Aspiration (FNA) sample will be summarized descriptively (Mean and Standard Deviation, Median, Minimum, and Maximum values, and proportion of samples yielding \>100,000 analyzable cells)

  At Day 4 and Week 3

Secondary Outcomes (2)

• Total number of adverse events related to lymph node sampling

  From Baseline to Week 3

• Total number of adverse events related to adenoid swab

  From Baseline to Week 3

Study Arms (2)

No immunotherapy (IT) Cohort

EXPERIMENTAL

Participants who have never been on cat immunotherapy will be assigned to this cohort Participants will undergo intradermal cat allergen challenge in bilateral upper arms at baseline (Day 1), will undergo axillary lymph node and peripheral blood sampling at Day 4, and axillary lymph node, peripheral blood, and adenoid and nasal sampling at Week 3. Lymph node sampling will occur in one axilla at Day 4 and in the contralateral axilla at Week 3

Drug: Intradermal cat allergen challenge

Subcutaneous Immunotherapy (SCIT) cohort

EXPERIMENTAL

Participants who have been on Subcutaneous Immunotherapy (SCIT) at maintenance dosing for at least 1 year will be assigned to this cohort. Participants will undergo intradermal cat allergen challenge in bilateral upper arms at baseline (Day 1), will undergo axillary lymph node and peripheral blood sampling at Day 4, and axillary lymph node, peripheral blood, and adenoid and nasal sampling at Week 3. Lymph node sampling will occur in one axilla at Day 4 and in the contralateral axilla at Week 3

Drug: Intradermal cat allergen challenge

Interventions

Intradermal cat allergen challenge DRUG

Participants will undergo intradermal cat allergen challenge in bilateral upper arms at baseline (Day 1)

No immunotherapy (IT) Cohort; Subcutaneous Immunotherapy (SCIT) cohort

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Participant must be able to understand and provide informed consent
• A clinical history of moderate to severe rhinoconjunctivitis symptoms caused by cat exposure, such that exposure is currently, or was historically to the initiation of treatment, interfering with usual daily activities or with sleep, as defined according to the ARIA classification of rhinitis
• Skin prick test wheal greater than or equal to 5 mm to standardized cat extract or cat-specific IgE greater than or equal to 0.7 kU/L obtained within 5 years of screening. These can be obtained from medical records if available from the prior 5 years, or at the screening visit if not
• Female participants of childbearing potential must have a negative pregnancy test at the screening visit prior to performing study procedures

You may not qualify if:

• Inability or unwillingness of a participant to give written informed consent or comply with study protocol
• Current household exposure to cat or regular occupational exposure to cat
• For participants in No immunotherapy (IT) cohort, any previous immunotherapy treatment with cat allergen
• For participants in No IT cohort, any current treatment with any form of allergen immunotherapy
• A history of grade 4 anaphylaxis due to any cause as defined by the WAO grading criteria
• Partially controlled or uncontrolled asthma as per Global Initiative for Asthma (GINA) guidelines in the 4 weeks prior to screening. Participants may be rescreened once asthma is well-controlled
• Severe asthma as defined by GINA guidelines in the previous 12 months
• History of emergency visit or hospital admission for asthma in the previous 12 months
• History of chronic obstructive pulmonary disease
• History of recurrent acute sinusitis, defined as 2 episodes per year for the last 2 years, all of which required antibiotic treatment
• History of chronic sinusitis, defined as sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness
• History of disease affecting the immune system such as autoimmune disease (e.g., systemic lupus erythematosus), immune complex disease (e.g., serum sickness), or immunodeficiency, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study
• History of malignancy of any type, excluding basal cell and squamous cell cancers of the skin that only required surgical excision or in situ carcinoma of the cervix study provided that curative therapy was completed at least 12 months prior to informed consent
• Any of the following:
• Inhaled tobacco, vaping, or use of inhaled illicit substances within 6 weeks of screening

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (1)

Brigham and Women's Hospital: Division of Allergy and Clinical Immunology

Boston, Massachusetts, 02215, United States

RECRUITING

Related Links

• Division of Allergy, Immunology, and Transplantation
• National Institute of Allergy and Infectious Diseases
• Immune Tolerance Network (ITN)

MeSH Terms

Conditions

Hypersensitivity

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

• Carolyn Baloh, M.D.

  Brigham and Women's Hospital: Division of Allergy and Clinical Immunology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Tanya M Laidlaw, MD

CONTACT

617-732-9850; tlaidlaw@bwh.harvard.edu

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 25, 2026
• First Posted: March 4, 2026
• Study Start: April 10, 2026
• Primary Completion (Estimated): January 27, 2027
• Study Completion (Estimated): January 27, 2027
• Last Updated: May 1, 2026

Record last verified: 2026-04

Locations

US (1)